Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.6%

13 terminated/withdrawn out of 233 trials

Success Rate

94.0%

+7.5% vs industry average

Late-Stage Pipeline

12%

29 trials in Phase 3/4

Results Transparency

79%

161 of 205 completed trials have results

Key Signals

4 recruiting161 with results12 terminated

Enrollment Performance

Analytics

Phase 1

170(78.0%)

Phase 3

20(9.2%)

Phase 2

14(6.4%)

Phase 4

9(4.1%)

N/A

5(2.3%)

218Total

Phase 1(170)

Phase 3(20)

Phase 2(14)

Phase 4(9)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (233)

Showing 20 of 233 trials

NCT03755804Phase 2Active Not Recruiting

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Role: collaborator

NCT01733082Recruiting

The Mycophenolate Pregnancy Registry

Role: collaborator

NCT06997198Phase 4Not Yet Recruiting

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

Role: collaborator

NCT04693533Phase 4Terminated

Fremanezumab, Migraine and Sleep

Role: collaborator

NCT06173661Phase 4Active Not Recruiting

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

Role: collaborator

NCT06742957Phase 3Completed

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Role: lead

NCT02938858Active Not Recruiting

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Role: collaborator

NCT04976192Phase 3Completed

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Role: lead

NCT07029126Recruiting

Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity

Role: collaborator

NCT00404989Recruiting

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Role: collaborator

NCT05831566Phase 3Recruiting

Expertise Asthma COPD Program with Digital Support

Role: collaborator

NCT02214381Phase 3Completed

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Role: collaborator

NCT05550337Phase 3Completed

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Role: lead

NCT00904943Phase 1Completed

Topiramate 25 mg Capsules Under Fed Conditions